GH Axis Research
Studied for its interaction with growth hormone secretion pathways.
Overview
CJC/IPA combines CJC-1295 No DAC, a growth-hormone-releasing hormone (GHRH) analog, with Ipamorelin, a selective growth hormone secretagogue, studied together for their complementary roles in GH-axis research.
Suria's CJC/IPA is formulated for high-purity, multi-compound peptide research, with analytical documentation to be made available through Suria's Batch Documentation system, supporting consistent, well-documented combination-protocol research.
Research Use Only. Not for human or veterinary use.
Specifications
Certificate of Analysis
Certificate of Analysis
Checking certificate…
Other documentation: Batch Documentation.
Research Highlights
Studied for its interaction with growth hormone secretion pathways.
Combines a GHRH-receptor pathway analogue with a ghrelin-receptor secretagogue for study of complementary GH-axis signaling.
Designed for research involving two distinct upstream signaling mechanisms that influence growth-hormone release.
Consistent, well-documented starting material for endocrine pathway research.
Storage
Store at −20°C, protected from light and moisture, until ready for reconstitution.
Store at 2–8°C and use within the laboratory's established handling window.
Avoid repeated freeze-thaw cycles to help preserve peptide integrity across a research protocol.
Research Use Only. Not for human consumption.
Frequently Asked Questions
Batch Documentation